Soleno Therapeutics (SLNO) Operating Leases (2021 - 2026)

Soleno Therapeutics (SLNO) has 6 years of Operating Leases data on file, last reported at $3.2 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $3.2 million, up 35.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 35.54% YoY), and the FY2025 annual result was $2.0 million, down 20.55% from the prior year.
• Operating Leases advanced to $3.2 million in Q1 2026 per SLNO's latest filing, from $2.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $3.2 million in Q1 2026 and troughed at $37000.0 in Q1 2024.
• A 5-year average of $1.5 million and a median of $2.0 million in 2025 frame the typical range for Operating Leases.
• On a YoY basis, Operating Leases climbed as much as 6281.08% in 2025 and fell as far as 20.55% in 2025.
• A 5-year view of Operating Leases shows it stood at $79000.0 in 2022, then advanced by 26.58% to $100000.0 in 2023, then surged by 2372.0% to $2.5 million in 2024, then slipped by 20.55% to $2.0 million in 2025, then jumped by 62.93% to $3.2 million in 2026.
• Business Quant data shows SLNO's Operating Leases at $3.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.